Skip to main content

Table 5 Time to symptom clearance for individual symptoms by day 10

From: Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

  Arm 1:
HCQ + SOC
Arm 2:
SOC
  No. patients Median (IQR) days No. patients Median (IQR) days
Overall 36 3 (2–5) 29 3 (2–4)
General symptoms     
 Fever 5 1 (1–2) 4 1 (1–3)
 Tiredness 5 1 (1–1) 3 1 (1–2)
 Muscle aches 4 2 (1–3) 5 1 (1–1)
Cardio-respiratory symptoms
 Cough 20 3 (2–4) 14 4 (2–5)
 Running nose 11 1 (1–3) 4 2 (1–3)
 Nasal congestion 4 4 (3–5) 3 2 (1–5)
 Sore throat 3 1 (1–3) 2 1 (1–1)
 Difficulty in breathing 1 1 (1–1) 0 0
 Chest pain 7 1 (1–4) 5 2 (1–3)
Neurological symptoms     
 Headache 14 2 (1–3) 11 2 (1–5)
 Dizziness 1 1 (1–1) 3 2 (1–4)
 Loss of smell 6 2 (1–3) 4 1 (1–3)
 Loss of taste 4 1 (1–2) 4 1 (1–1)
Gastrointestinal     
 Poor appetite 5 3 (1–5) 4 1 (1–2)
 Nausea 1 1 (1–1) 0 N/A
 Vomiting 1 1 (1–1) 0 N/A
 Abdominal pain 4 1 (1–3) 2 2 (1–3)
 Diarrhea 1 1 (1–1) 1 5 (5–5)